SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway

A ginsenoside F2-enhanced mixture (SGL 121) increases the content of ginsenoside F2 by biotransformation. In the present study, we investigated the effect of SGL 121 on nonalcoholic fatty liver disease (NAFLD) in vitro and in vivo. High-fat, high-carbohydrate-diet (HFHC)-fed mice were administered S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Da Eun, Chang, Bo Yoon, Jeon, Byeong Min, Baek, Jong In, Kim, Sun Chang, Kim, Sung Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352188/
https://www.ncbi.nlm.nih.gov/pubmed/32630596
http://dx.doi.org/10.3390/ijms21124534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352188/
https://www.ncbi.nlm.nih.gov/pubmed/32630596
http://dx.doi.org/10.3390/ijms21124534

Ejemplares similares